News

Vanguard Clinical Research has begun conducting trials an oral medication to relieve symptoms for people with a mild to moderate infection. “The research has been approved for 100 patients. Those are people who either think they have COVID-19, for which they’ll be tested, or they may have a common cold,” said Dr. Alan Tannenbaum, medical director of the clinical research team at Vanguard Clinical Research. In addition to helping clinical trials at facilities, Yourway is helping to lead the charge toward a more patient-centric supply chain by offering direct-to-patient services.

Canada-based Appili Therapeutics has enrolled and dosed the first cluster of participants in its Phase II CONTROL COVID-19 clinical trial of favipiravi, developed by FUJIFILM Toyama Chemical. Yourway has a local depot that’s 6,000 square feet conveniently located in Toronto, Canada to better serve the clinical trial needs in the country.

Moderna has wrapped phase III enrollment of its COVID-19 vaccine clinical trials. The company issued a statement regarding trial demographics, noting that high-risk groups make up 42% of the trial and 37% have a diverse background. With 21 strategically located global depots, Yourway can help facilitate trials worldwide.

A volunteer in a trial for a COVID-19 vaccine sponsored by AstraZeneca and Oxford University has reportedly passed away in Brazil. The clinical trials are on hold in the U.S. but are ongoing in the UK and Brazil. As a clinical supplies premium courier, Yourway can deliver worldwide in hours not days.

Moncef Slaoui, co-leader of the U.S. government’s Operation Warp Speed effort has announced that he believes Moderna’s and Pfizer’s COVID-19 mRNA vaccines will be successful in clinical trials, leading to nationwide immunization by mid-2021. In order to ensure that clinical trials are successful sponsor organizations must partner with experienced logistics service providers like Yourway.

Exogenesis Corporation announced that it had acheived the primary endpoints of trapping and deactivating SARS-CoV-2 in simulated real-world exposures in a series of challenge tests for the Exogenesis Surgical Mask (ESM), a protective nose and mouth covering for healthcare workers and patients involved in medical and surgical procedures. Any innovation that enhances patient and clinician safety is welcome news to Yourway and our clients trying to conduct clinical trials during the pandemic.

The U.S. Food and Drug Administration announced that it awarded six new clinical trial research grants to principal investigators from academia and industry totaling over $16 million over the next four years. These trial research grants, awarded through the Congressionally funded Orphan Products Grants Program, enhance the development of medical products for patients with rare diseases. Yourway fully understands the challenges conducting clinical trials for rare diseases, and provides a range of integrated solutions to overcome them.

ResearchandMarkets is offering a new report detailing and forecasting the global market for 3D printed drugs. 3D printed drugs are medications that are designed by 3D printing technique to provide safe and effective customized drugs to the individuals. The advantages of 3D printing such as its ability to offer personalized medicine system with an automated control over drug dose and suitability for both low and high drug concentrations allow drug companies to attain boosted efficacy and adherence of drugs as well as focus on their brand longevity. Yourway is a strong supporter of patient-centric innovations.

The CoVIg-19 Plasma Alliance confirmed that patients are being enrolled in the Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) phase III clinical trial sponsored by NIAID, part of the NIH. The trial will evaluate the safety, tolerability and efficacy of an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine for treating hospitalized adults at risk for serious complications of COVID-19 disease. If successful, it may become one of the earliest treatment options for hospitalized COVID-19 patients. Like the entire global population, Yourway is paying close attention to the development of more effective therapeutics for COVID-19 and ready to support these efforts regardless of urgency.

Impel NeuroPharma presented patient-reported outcomes data from the company's pivotal phase III, open-label study "STOP 301" of INP104 (dihydroergotamine mesylate) using the company's proprietary POD technology, for the treatment of acute migraine. Yourway is committed to supporting clinical trials for unmet medical needs.